Entering text into the input field will update the search result below

Advaxis inks deal for commercialization of lead product candidate in Latin America

  • Advaxis (ADXS +9.2%) enters into a co-development and commercialization agreement with privately held Mexican specialty pharmaceutical firm Especificos Stendhal SA de CV for axalimogene filolisbac (formerly ADXS-HPV) in HPV-associated cancers.
  • Under the terms of the deal, Stendahl will pay $10M toward the expenses of conducting a planned global Phase 3 study, AIM2CERV, assessing axalimogene filolisbac in women with high-risk, locally advanced cervical cancer. Advaxis will assist Stendahl to complete the study in Latin American markets while Stendahl will manage the regulatory approval process and commercialization activities.
  • The companies will share profits on an undisclosed basis.
  • Axalimogene filolisbac is an immunotherapy based on the company's Lm Technology, which uses live attenuated bioengineered Listeria bacteria to deliver a fusion protein inside cancer cells which then stimulates the immune system to attack the cancer.

Recommended For You

About ADXS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ADXS--
Ayala Pharmaceuticals, Inc.